SEP 28, 2021 9:00 AM PDT

The FDA approves drug to treat a bad cholesterol in children

WRITTEN BY: J. Bryce Ortiz

Familial hypercholesterolemia (FH) is a genetic disorder that afflicts approximately 1 in 250 people. Interestingly, while it is estimated that more than one million people in the United States have FH, less than 10% of these individual know they have it. FH is a disorder in which individuals have significantly high blood levels of low-density lipoprotein (LDL) cholesterol, more commonly known as “bad cholesterol.” When blood levels of this bad cholesterol become high, and remain high for extended periods of time, the cholesterol can accumulate into the walls of blood vessels which raises the chances of serious health problems such as heart attack or stroke. 

For most people, maintaining low levels of LDL cholesterol can be accomplished through lifestyle choices such as choosing a healthy diet, proper exercise, and quitting smoking. However, individuals who are affected by FH have high cholesterol levels early in life. This has many detrimental effects and in these individuals heart disease my start to develop earlier than the normal population, leading to heightened risks for heart attack and stroke at a young age. Because of this, early and frequent diagnostic testing has been encouraged for anyone with a family member with high cholesterol. 

Once an individual is diagnosed with FH, treatment can begin. These treatments include lifestyle changes or improvements in diet and exercise, and drug regimens. While there are many drugs to treat high cholesterol, many of the recently approved medications for FH were not approved for children of all ages. However, last week, the United States Food and Drug Administration (FDA) approved the drug Repatha (Manufactured by Amgen Inc.) for use in children as young as 10-years old. After the approval, David M. Reese, MD, vice president of research and development at Amgen said, “The approval of Repatha for pediatric patients with FH represents a much-needed adjunct treatment option for these children with genetically high cholesterol who are unable to manage their high LDL-C with other lipid-lowering agents alone.”

The FDA based their approval on recent clinical data in children aged 10-17 years old. The participants in the study had FH and received a single injection of Repatha monthly for 6 months. When the blood LDL levels of these patients were compared to patients who were not administered Repatha, the researchers found a 38% reduction in blood LDL levels. The approval of this lifesaving medication is a welcomed relief for pediatric FH patients, their families, and advocates. 

 

Sources: CDCMedlinePlusThe Cleveland ClinicThe FH foundationFDARepathaAmgen

About the Author
Doctorate (PhD)
Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
DEC 01, 2022
Cannabis Sciences
Study Finds CBD Does Not Reduce the Psychoactive High Caused by THC
Study Finds CBD Does Not Reduce the Psychoactive High Caused by THC
Researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London found ...
DEC 04, 2022
Cannabis Sciences
Increasing Interest in Psychoactive Treatments for Mood Disorders
Increasing Interest in Psychoactive Treatments for Mood Disorders
Findings from various studies presented at the Society for Neuroscience 2022 annual meeting highlighted the need for inn ...
DEC 07, 2022
Drug Discovery & Development
"Study May Proceed" for Major Depressive Disorder Drug
"Study May Proceed" for Major Depressive Disorder Drug
Vistagen is a clinical-stage pharma company developing drugs for central nervous system disorders (CNS disorders) such a ...
DEC 25, 2022
Neuroscience
Researchers Reveal the Signals That Cause Chronic Gut Pain
Researchers Reveal the Signals That Cause Chronic Gut Pain
Many people suffer from abdominal pain caused by gastrointestinal disorders that cause excessive inflammation and disrup ...
JAN 05, 2023
Neuroscience
Fear Memories are Stored in Prefrontal Cortex
Fear Memories are Stored in Prefrontal Cortex
A University of California, Riverside research team examined how the brain processes and stores memories of traumatic ex ...
JAN 12, 2023
Drug Discovery & Development
First AI-Discovered Drug has positive results in Phase 1 Trials
First AI-Discovered Drug has positive results in Phase 1 Trials
Insilico Medicine is a clinical-stage artificial-intelligence (AI)-based research and development company seeking to dis ...
Loading Comments...